Quality of life in children with osteogenesis imperfecta treated with oral bisphosphonates (Olpadronate): a 2-year randomized placebo-controlled trial

[1]  J. Troendle,et al.  Controlled Trial of Pamidronate in Children With Types III and IV Osteogenesis Imperfecta Confirms Vertebral Gains but Not Short‐Term Functional Improvement , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  C. Uiterwaal,et al.  A difference in perception of quality of life in chronically ill children was found between parents and pediatricians. , 2005, Journal of clinical epidemiology.

[3]  L. Tatò,et al.  Intravenous Neridronate in Children With Osteogenesis Imperfecta: A Randomized Controlled Study , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  R. Engelbert,et al.  Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study , 2004, The Lancet.

[5]  P. Helders,et al.  Osteogenesis imperfecta in childhood: impairment and disability. A prospective study with 4-year follow-up. , 2004, Archives of physical medicine and rehabilitation.

[6]  P. Helders,et al.  Osteogenesis imperfecta in childhood: effects of spondylodesis on functional ability, ambulation and perceived competence , 2004, European Spine Journal.

[7]  M. Shevlin,et al.  The Self-Perception Profile for Children (SPPC): a multiple-indicator multiple-wave analysis using LISREL , 2003 .

[8]  D. Feeny,et al.  The Health Utilities Index (HUI®): concepts, measurement properties and applications , 2003, Health and quality of life outcomes.

[9]  F. Glorieux,et al.  Osteogenesis imperfecta--clinical and molecular diversity. , 2003, European cells & materials.

[10]  L. Gerber,et al.  Temperament and physical performance in children with osteogenesis imperfecta. , 2003, Pediatrics.

[11]  F. Glorieux,et al.  Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. , 2002, Bone.

[12]  M. Boyle,et al.  Multiattribute and Single‐Attribute Utility Functions for the Health Utilities Index Mark 3 System , 2002, Medical care.

[13]  F. Glorieux,et al.  Osteogenesis Imperfecta Type VI: A Form of Brittle Bone Disease with a Mineralization Defect , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  P. Helders,et al.  Osteogenesis imperfecta in childhood: perceived competence in relation to impairment and disability. , 2001, Archives of physical medicine and rehabilitation.

[15]  D. Feeny,et al.  The Health Utilities Index (HUI®) system for assessing health-related quality of life in clinical studies , 2001, Annals of medicine.

[16]  P. Helders,et al.  Osteogenesis imperfecta in childhood: prognosis for walking. , 2000, The Journal of pediatrics.

[17]  F. Glorieux,et al.  Type V Osteogenesis Imperfecta: A New Form of Brittle Bone Disease , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  P. Helders,et al.  Osteogenesis imperfecta: profiles of motor development as assessed by a postal questionnaire , 2000, European Journal of Pediatrics.

[19]  F. Glorieux,et al.  Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. , 2000, The Journal of clinical endocrinology and metabolism.

[20]  A. Erling.  Methodological considerations in the assessment of health‐related quality of life in children , 1999, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[21]  F. Glorieux,et al.  Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. , 1998, The New England journal of medicine.

[22]  S. Söderhäll,et al.  Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta , 1998, Acta paediatrica.

[23]  G. Massa,et al.  Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate) , 1997, European Journal of Pediatrics.

[24]  S. Papapoulos,et al.  Long‐Term Effects of Bisphosphonates on the Growing Skeleton: Studies of Young Patients with Severe Osteoporosis , 1997, Medicine.

[25]  P. Helders,et al.  Osteogenesis imperfecta in childhood: impairment and disability. , 1997, Pediatrics.

[26]  J. Pater.  Quality of life and pharmacoeconomics in clinical trials , 1996 .

[27]  G. Bonsel,et al.  Reliability and validity of a comprehensive health status measure in a heterogeneous population of children admitted to intensive care. , 1996, Journal of clinical epidemiology.

[28]  M. Boyle,et al.  Reliability of the Health Utilities Index—Mark III used in the 1991 cycle 6 Canadian General Social Survey Health Questionnaire , 1995, Quality of Life Research.

[29]  A Laupacis,et al.  The effect of elective total hip replacement on health-related quality of life. , 1993, The Journal of bone and joint surgery. American volume.

[30]  H. Koot,et al.  Cross-Cultural Validation of Harter'S Self-Perception Profile for Children in a Dutch Sample , 1993 .

[31]  P. Byers,et al.  Osteogenesis imperfecta type I is commonly due to a COL1A1 null allele of type I collagen. , 1992, American journal of human genetics.

[32]  P. Byers,et al.  Inherited disorders of collagen gene structure and expression. , 1989, American journal of medical genetics.

[33]  A. Laupacis,et al.  Randomized trials in orthopaedics: why, how, and when? , 1989, The Journal of bone and joint surgery. American volume.

[34]  E E Bleck,et al.  Nonoperative treatment of osteogenesis imperfecta: orthotic and mobility management. , 1981, Clinical orthopaedics and related research.

[35]  D. Sillence,et al.  Genetic heterogeneity in osteogenesis imperfecta. , 1979, Journal of medical genetics.

[36]  L. Dimeglio,et al.  A Comparison of Oral and Intravenous Bisphosphonate Therapy for Children with Osteogenesis Imperfecta , 2005, Journal of pediatric endocrinology & metabolism : JPEM.

[37]  M. Zacharin,et al.  Pamidronate Treatment of Less Severe Forms of Osteogenesis Imperfecta in Children , 2004, Journal of pediatric endocrinology & metabolism : JPEM.

[38]  W. Bleyer.  Cancer in older adolescents and young adults: epidemiology, diagnosis, treatment, survival, and importance of clinical trials. , 2002, Medical and pediatric oncology.

[39]  M. Villaronga,et al.  Efficacy of Low Dose Schedule Pamidronate Infusion in Children with Osteogenesis Imperfecta , 2001, Journal of pediatric endocrinology & metabolism : JPEM.

[40]  M. Boyle,et al.  Multiplicative Multi-Attribute Utility Function for the Health Utilities Index Mark 3 (HUI3) System: A Technical Report , 1998 .

[41]  B. Spilker,et al.  Quality of life and pharmacoeconomics in clinical trials , 1996 .